China has reinforced its commitment to combating the illicit production and distribution of fentanyl-related substances through a newly released white paper, underscoring its rigorous regulatory framework and international collaboration. Titled 'Controlling Fentanyl-Related Substances – China’s Contribution,' the document outlines China’s multi-pronged approach to addressing one of the world’s most pressing public health challenges.
According to the paper, China now classifies fentanyl-related medications under its List of Controlled Narcotic Drugs, enforcing strict oversight of their manufacturing, sale, and export. Advanced tracking technologies—such as radio frequency identification, the Internet of Things, and artificial intelligence—are deployed to monitor the entire supply chain, minimizing risks of diversion or misuse.
International partnerships are a cornerstone of China’s strategy. The white paper highlights cooperative efforts with the United States and other countries to tackle fentanyl trafficking and precursor chemical smuggling. 'China firmly opposes finger-pointing and advocates shared responsibility,' the document states, emphasizing collective action over unilateral blame.
In line with its vision for a 'global community of shared future,' China has expanded controlled substance lists, tightened inspections, and promoted innovative regulatory methods. The country also reaffirmed its role in shaping international drug control policies, contributing 'Chinese wisdom' to global governance efforts.
As synthetic drug threats evolve, China’s measures signal a proactive stance, balancing domestic enforcement with cross-border diplomacy to curb the fentanyl crisis.
